Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 11/20 | 0.56 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.43 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | SMO | Q99835 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21217815 | 0.97 | ROCK2 (0.53) | ROCK2TNIKCACNA2D1ROCK1MEN1 | |
| SCHEMBL24610341 | 0.90 | TNIK (0.45) | ROCK2TNIKCACNA2D1ROCK1MEN1 | |
| SCHEMBL21217893 | 0.87 | ROCK1 (0.46) | ROCK2ROCK1MEN1KMT2ANPC1 | |
| SCHEMBL24094324 | 0.87 | TNIK (0.43) | ROCK2TNIKCACNA2D1ROCK1MEN1 | |
| SCHEMBL22966756 | 0.87 | MEN1 (0.44) | ROCK2TNIKCACNA2D1ROCK1MEN1 | |
| SCHEMBL22966729 | 0.86 | TNIK (0.44) | ROCK2TNIKCACNA2D1ROCK1MEN1 | |
| Hydrochloric Acid SCHEMBL21198685 | 0.86 | ROCK1 (0.46) | ROCK2ROCK1MEN1KMT2ANPC1 | |
| SCHEMBL21217865 | 0.86 | MEN1 (0.43) | ROCK2TNIKCACNA2D1ROCK1MEN1 | |
| SCHEMBL24610250 | 0.86 | ROCK2 (0.42) | ROCK2TNIKCACNA2D1ROCK1MEN1 | |
| SCHEMBL21217532 | 0.85 | TNIK (0.44) | ROCK2TNIKCACNA2D1ROCK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034140-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LTD (GB) | 2026-02-05 | — | — | US | disclosed |
| US-12453734-B2 | Modulators of rho-associated protein kinase | REDX PHARMA LIMITED (GB) | 2025-10-28 | — | — | US | disclosed |
| US-20240216386-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2024-07-04 | — | — | US | disclosed |
| US-11878020-B2 | Modulators of Rho-associated protein kinase | REDX PHARMA PLC (GB) | 2024-01-23 | — | — | US | disclosed |
| US-20230021916-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
| US-11497751-B2 | Modulators of Rho-associated protein kinase | REDX PHARMA PLC (GB) | 2022-11-15 | — | — | US | disclosed |
| EP-4026834-A1 | HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | Redx Pharma Plc (GB) | 2022-07-13 | — | — | EP | disclosed |
| EP-3743420-B1 | HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA PLC (GB) | 2021-12-15 | — | — | EP | disclosed |
| US-20210038606-A1 | Modulators of Rho-associated Protein Kinase | REDX PHARMA LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
| EP-3743420-A1 | HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | Redx Pharma Plc (GB) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019145729-A9 | HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA PLC (GB) | 2020-07-30 | — | — | WO | disclosed |
| WO-2019145729-A1 | HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA PLC (GB) | 2019-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034140-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK1, ROCK2, RHOA | ROCK2 2/4885TNIK 288/4885CACNA2D1 1597/4885 |
| US-12453734-B2 | Modulators of rho-associated protein kinase | ROCK2, ROCK1, RHOA | ROCK2 1/4885TNIK 249/4885CACNA2D1 3644/4885 |
| US-20240216386-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK2, ROCK1, RHOA | ROCK2 1/4885TNIK 249/4885CACNA2D1 3644/4885 |
| US-11497751-B2 | Modulators of Rho-associated protein kinase | ROCK2, ROCK1, RHOA | ROCK2 1/4885TNIK 251/4885CACNA2D1 3693/4885 |
| US-20210038606-A1 | Modulators of Rho-associated Protein Kinase | ROCK2, ROCK1, RHOA | ROCK2 1/4885TNIK 251/4885CACNA2D1 3693/4885 |
| US-11878020-B2 | Modulators of Rho-associated protein kinase | ROCK2, ROCK1, RHOA | ROCK2 1/4885TNIK 249/4885CACNA2D1 3644/4885 |
| US-20230021916-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK2, ROCK1, RHOA | ROCK2 1/4885TNIK 249/4885CACNA2D1 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.